Associations of circulating 25-hydroxyvitamin D with prostate cancer diagnosis, stage and grade

Rebecca Gilbert*, Chris Metcalfe, William D. Fraser, Jenny Donovan, Freddie Hamdy, David E. Neal, J. Athene Lane, Richard M. Martin

*Corresponding author for this work

Research output: Contribution to journalArticle (Academic Journal)peer-review

57 Citations (Scopus)

Abstract

Epidemiological studies suggest that vitamin D protects against prostate cancer, although evidence is limited and inconsistent. We investigated associations of circulating total 25-hydroxyvitamin D (25(OH)D) with prostate specific antigen-detected prostate cancer in a case-control study nested within the prostate testing for cancer and treatment (ProtecT) trial. Conditional logistic regression was used to estimate odds ratios (ORs) and 95% confidence intervals (CIs) quantifying the association between circulating total 25(OH)D and prostate cancer. In case-only analyses, we used unconditional logistic regression to quantify associations of total 25(OH)D with stage (advanced vs. localized) and Gleason grade (high-grade (=7) vs. low-grade (

Original languageEnglish
Pages (from-to)1187-1196
Number of pages10
JournalInternational Journal of Cancer
Volume131
Issue number5
DOIs
Publication statusPublished - 1 Sep 2012

Structured keywords

  • BTC (Bristol Trials Centre)
  • Centre for Surgical Research

Keywords

  • prostate cancer
  • vitamin D
  • 25-hydroxyvitamn D
  • VITAMIN-D STATUS
  • UNITED-STATES
  • AFRICAN-AMERICANS
  • SUBSEQUENT RISK
  • MEN
  • MORTALITY
  • 1,25-DIHYDROXYVITAMIN-D
  • D-1-ALPHA-HYDROXYLASE
  • EPIDEMIOLOGY
  • CALCITRIOL

Fingerprint Dive into the research topics of 'Associations of circulating 25-hydroxyvitamin D with prostate cancer diagnosis, stage and grade'. Together they form a unique fingerprint.

Cite this